5,663 Shares in Hologic, Inc. $HOLX Acquired by United Services Automobile Association

Key Points

• United Services Automobile Association invested approximately $347,000 in Hologic, acquiring 5,663 shares of the medical equipment provider in the 1st quarter.
• Hologic received several upgrades from analysts, with ratings shifting from "hold" to "buy," and a consensus target price set at $78.00.
• Hologic's recent earnings report showed an EPS of $1.08, exceeding estimates, along with a revenue of $1.02 billion for the quarter.

United Services Automobile Association bought a new position in Hologic, Inc. (NASDAQ:HOLX - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 5,663 shares of the medical equipment provider's stock, valued at approximately $347,000.

Other hedge funds also recently made changes to their positions in the company. Zions Bancorporation National Association UT bought a new stake in shares of Hologic during the first quarter valued at approximately $34,000. Allworth Financial LP raised its holdings in shares of Hologic by 46.0% during the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock valued at $40,000 after buying an additional 216 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich bought a new stake in shares of Hologic during the first quarter valued at approximately $42,000. Larson Financial Group LLC raised its holdings in shares of Hologic by 6,016.7% during the first quarter. Larson Financial Group LLC now owns 734 shares of the medical equipment provider's stock valued at $45,000 after buying an additional 722 shares during the last quarter. Finally, Raiffeisen Bank International AG bought a new stake in shares of Hologic during the fourth quarter valued at approximately $49,000. Institutional investors own 94.73% of the company's stock.

Hologic Price Performance

Hologic stock traded down $0.65 during mid-day trading on Monday, hitting $63.80. The company's stock had a trading volume of 1,276,134 shares, compared to its average volume of 2,649,058. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $14.19 billion, a P/E ratio of 26.47, a P/E/G ratio of 2.34 and a beta of 0.57. Hologic, Inc. has a twelve month low of $51.90 and a twelve month high of $84.39. The stock's fifty day moving average price is $66.43 and its two-hundred day moving average price is $62.64.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.03. The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The firm's quarterly revenue was up 1.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.06 earnings per share. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on HOLX shares. Mizuho set a $75.00 price target on Hologic in a report on Thursday, July 31st. Argus raised Hologic from a "hold" rating to a "buy" rating and set a $80.00 price target on the stock in a report on Monday, August 18th. UBS Group raised their price objective on shares of Hologic from $65.00 to $70.00 and gave the company a "neutral" rating in a research note on Thursday, July 31st. Morgan Stanley raised their price objective on shares of Hologic from $65.00 to $69.00 and gave the company an "equal weight" rating in a research note on Thursday, July 31st. Finally, Evercore ISI raised their price objective on shares of Hologic from $62.00 to $68.00 and gave the company an "in-line" rating in a research note on Tuesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $78.00.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.